Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study

BACKGROUND: In recent years, several biosimilar drugs, including those of infliximab, have obtained marketing authorization from the European Medicines Agency (EMA). Given the peculiarity of the safety profile of biological medical products (originator and biosimilars), the evaluation of their toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Scavone, Cristina, Sessa, Maurizio, Clementi, Emilio, Corrao, Giovanni, Leone, Roberto, Mugelli, Alessandro, Rossi, Francesco, Spina, Edoardo, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290713/
https://www.ncbi.nlm.nih.gov/pubmed/30341487
http://dx.doi.org/10.1007/s40259-018-0313-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290713/
https://www.ncbi.nlm.nih.gov/pubmed/30341487
http://dx.doi.org/10.1007/s40259-018-0313-2

Ejemplares similares